Brief: Mirati Therapeutics Announces U.S. FDA Accelerated Approval Of Krazati™ As A Targeted Treatment Option For Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer With A Krasg12c Mutation
12/12/2022 23:20
Dec 12 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* MIRATI THERAPEUTICS ANNOUNCES U.S. FDA ACCELERATED
APPROVAL OF
KRAZATI™ (ADAGRASIB) AS A TARGETED TREATMENT OPTION FOR PATIENTS
WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
(NSCLC) WITH A KRASG12C MUTATION
* $19,750 FOR 200MG TABLET/180 COUNT BOTTLE FOR KRAZATI
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)